RHRiley D. Hellinger

Riley D. Hellinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Riley D. Hellinger has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Goulet

    The David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA

    3 shared publications
  • Michael T. Hemann

    The David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA

    3 shared publications
  • Aviv Regev

    Department of Biology, Massachusetts Institute of Technology, Cambridge, USA

    2 shared publications
  • Azucena Ramos

    Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA

    2 shared publications
  • Catherine E. Koch

    Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA

    2 shared publications
  • Julia Fröse

    Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA

    2 shared publications

Latest Publications

  • Tumor cell–intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer

    by Julia Fröse, Evelyn Chen, Charles A. Whittaker, Paul Leclerc, Sean Doherty, Adam Langenbucher, Jasmine Shao, Riley D. Hellinger, Daniel Goulet, Tuomas Tammela, et al.

    Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematologic cancers but has shown limited efficacy in solid tumors, including pancreatic ductal adenocarcinoma (PDAC). The cellular and molecular factors that influence CAR T cell therapy response remain largely unknown. By integrating modular in vivo CRISPR screens with single-cell genomics and immunocompetent orthotopic models of PDAC, we uncover oxidative and proteotoxic stress pathways as previously unknown modulators of CAR T cell therapy response. Disruption of stress regulatory genes, particularly Keap1 and Slc33a1 , sensitizes PDAC tumors to CAR T cell killing in vivo. Hyperactivation of the Nrf2 pathway by genetic ablation of Keap1 or endogenous engineering of clinically observed Keap1 or Nfe2l2 mutations enhances tumor susceptibility to CAR T cell therapy. Thus, tumor-intrinsic molecular stress phenotypes can induce unexpected cell state–specific vulnerabilities to cell-based immunotherapies. These findings provide a foundation to improve efficacy of CAR T cell therapy in solid malignancies and to better stratify patients with cancer by tumor genotype.

  • The impact of estrogen replacement during perimenopause on lung function and airway inflammation in the VCD mouse model

    by William P. Pederson, Laurie Michelle Ellerman, Riley D. Hellinger, Joselyn Joanna Rojas Quintero, Francesca Polverino, John P. Konhilas, Julie G. Ledford

    Menopause-associated asthma is a subtype of asthma that is still largely unexplored and difficult to manage. Women experiencing menopause-associated asthma often have more severe exacerbations, higher rates of exacerbation, and most importantly, poor response to standard treatments. This study examined the impact of estrogen replacement given during the perimenopause phase on lung inflammation and function after menopause. While decreasing eosinophil recruitment, estrogen replacement actually led to worse lung function and more airway remodeling.

  • Open Access

    Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening

    by Azucena Ramos, Catherine E. Koch, Yunpeng Liu-Lupo, Riley D. Hellinger, Taeyoon Kyung, Keene L. Abbott, Julia Fröse, Daniel Goulet, Khloe S. Gordon, Keith P. Eidell, et al.

    CAR-T therapy is a promising, novel treatment modality for B-cell malignancies and yet many patients relapse through a variety of means, including loss of CAR-T cells and antigen escape. To investigate leukemia-intrinsic CAR-T resistance mechanisms, we performed genome-wide CRISPR-Cas9 loss-of-function screens in an immunocompetent murine model of B-cell acute lymphoblastic leukemia (B-ALL) utilizing a modular guide RNA library. We identified IFNγR/JAK/STAT signaling and components of antigen processing and presentation pathway as key mediators of resistance to CAR-T therapy in vivo; intriguingly, loss of this pathway yielded the opposite effect in vitro (sensitized leukemia to CAR-T cells). Transcriptional characterization of this model demonstrated upregulation of these pathways in tumors relapsed after CAR-T treatment, and functional studies showed a surprising role for natural killer (NK) cells in engaging this resistance program. Finally, examination of data from B-ALL patients treated with CAR-T revealed an association between poor outcomes and increased expression of JAK/STAT and MHC-I in leukemia cells. Overall, our data identify an unexpected mechanism of resistance to CAR-T therapy in which tumor cell interaction with the in vivo tumor microenvironment, including NK cells, induces expression of an adaptive, therapy-induced, T-cell resistance program in tumor cells.


  • Open Access

    Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening

    by Azucena Ramos, Catherine E. Koch, Yunpeng Liu, Riley D. Hellinger, Taeyoon Kyung, Keene L. Abbott, Julia Fröse, Daniel Goulet, Khloe S. Gordon, Rebecca C Larson, et al.

    CAR-T therapy is a promising new treatment modality for B-cell malignancies. However, the majority of patients inevitably go on to experience disease relapse through largely unknown means. To investigate leukemia-intrinsic CAR-T resistance mechanisms, we performed genome-wide CRISPR-Cas9 loss-of-function screens in an immunocompetent murine model of B-cell acute lymphoblastic leukemia (B-ALL) utilizing a novel, modular guide RNA library. We identified IFNγ/JAK/STAT signaling and components of antigen processing and presentation pathway as key mediators of resistance to CAR-T therapy in vivo , but not in vitro . Transcriptional characterization of this model demonstrated an upregulation of these pathways in CAR-T treated relapsed tumors, and examination of data from CAR-T treated patients with B-ALL revealed an association between poor outcomes and increased expression of JAK/STAT/MHC-I in leukemia cells. Overall, our data identify an unexpected mechanism of resistance to CAR-T therapy in which tumor cell interaction with CAR-T cells in vivo induces expression of an adaptive T-cell resistance program in tumor cells.